Amgen INC Form 4 insider transactions

Nancy Grygiel, SVP & CCO of Amgen, reports the disposition of common stock due to tax withholding related to vested restricted stock units.

Peter H. Griffith, EVP & CFO of Amgen Inc., reported disposing of common stock to cover tax obligations related to vested restricted stock units.

Jonathan P. Graham, EVP & General Counsel & Secretary of Amgen Inc., reported the disposal of shares to cover tax obligations related to vested restricted stock units.

EVP Murdo Gordon reports disposition of Amgen shares to cover tax obligations related to vested restricted stock units.

Matthew C. Busch, VP, Finance & CAO of Amgen Inc., reports the disposition and acquisition of Amgen common stock on May 2, 2025, including a sale of 1,000 shares.

Amgen's CEO, Robert Bradway, reported disposing of shares to cover tax obligations related to vested restricted stock units and dividend equivalents.

Esteban Santos, EVP, Operations at Amgen, disposed of 759 shares of common stock on April 30, 2025, to cover tax obligations related to vested restricted stock units.

EVP & Chief Technology Officer of Amgen, David M. Reese, reports disposing of 768 shares of common stock on April 30, 2025, to cover tax obligations.

Amgen's SVP of Human Resources, Derek Miller, disposed of 77 shares of common stock on April 30, 2025, to cover tax obligations, leaving him with 9,577 shares.

Amgen's SVP of Business Development, Rachna Khosla, reports the disposal of common stock to cover tax obligations.

Nancy A. Grygiel, SVP & CCO of Amgen, reports the disposal of 113 shares of common stock to cover tax obligations related to dividend equivalents.

Peter H. Griffith, EVP & CFO of Amgen Inc., reported the disposal of 640 shares of common stock on April 30, 2025, to cover tax obligations related to vested restricted stock units.

Jonathan P. Graham, EVP & General Counsel & Secretary of Amgen Inc., disposed of 728 shares of common stock on April 30, 2025, to cover tax obligations.

Murdo Gordon, EVP at Amgen, reports disposition of 800 common stock shares to cover tax obligations.

Matthew C. Busch, VP, Finance & CAO of Amgen Inc., reports the disposition of 18 shares of common stock to cover tax obligations.

Amgen's CEO, Robert Bradway, reports the disposition of shares to cover tax obligations and holdings through GRATs.

Esteban Santos, EVP of Operations at Amgen, reports the disposition of 3,393 shares of common stock to cover tax obligations related to vested restricted stock units.

Executive Vice President and Chief Technology Officer of Amgen, David M. Reese, reports the disposal of 3,635 shares of common stock to cover tax obligations.

Amgen's SVP of Human Resources, Derek Miller, disposed of 930 shares of common stock on March 17, 2025, to cover tax obligations arising from vested restricted stock units.

Amgen's SVP of Business Development, Rachna Khosla, reported the disposal of 489 shares of common stock to cover tax obligations.

Nancy A. Grygiel, SVP & CCO of Amgen Inc., reports the disposition of 524 shares of common stock to cover tax obligations related to vested restricted stock units and shares acquired under the company's 401(k) plan.

Peter H. Griffith, EVP & CFO of Amgen Inc., reports a transaction involving common stock on March 17, 2025, resulting in an adjusted beneficial ownership.

Jonathan P. Graham, EVP & General Counsel & Secretary of Amgen Inc., reports the disposal of 3,150 shares of common stock to cover tax obligations.

EVP Murdo Gordon disposed of 4,039 shares of Amgen common stock on March 17, 2025, to satisfy tax obligations related to vested restricted stock units.

Amgen's CEO, Robert Bradway, reported the disposal of shares to cover tax obligations related to vested restricted stock units (RSUs).

Matthew C. Busch, VP, Finance & CAO of Amgen Inc., reported disposing of 174 shares of common stock on March 17, 2025, to cover tax obligations related to vested restricted stock units.

Esteban Santos, EVP of Operations at Amgen, reports acquiring 6,792 shares of common stock and holding 78,338 shares directly, along with indirect ownership through the 401(k) plan.

David M. Reese, EVP & Chief Technology Officer of Amgen Inc., reports acquiring 7,277 shares of common stock on March 3, 2025.

Derek Miller, SVP of Human Resources at Amgen, reports acquiring 2,005 shares of common stock on March 3, 2025.

Amgen's SVP of Business Development, Rachna Khosla, reports acquiring 1,403 shares of common stock on March 3, 2025.